Abstract
T he transcatheter aortic valve implantation (TAVI, or TAVR, transcatheter aortic valve replacement), the treatment of choice for patients with severe aortic stricture deemed inoperable (class I, level of evidence B) and an alternative strategy for surgical valve replacement surgery in high-risk individuals (class IIa, level of evidence B), has been employed, to date, in over 700 patients in Brazil. This procedure was approved by the Brazilian Federal Council of Medicine in January 2012, after its evaluation as a non-experimental practice. This phase was subsequent to the approval of the device used in the procedure by the Brazilian Health Surveillance Agency (Agencia Nacional de Vigilância Sanitaria – ANVISA).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call